Print

Featured Studies Results

A New Drug, DT2216, Combined With Paclitaxel for Recurrent Platinum-Resistant Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/429 /a-new-drug-dt2216-combined-with-paclitaxel-for-recurrent-platinum-resistant-ovarian-cancer

Clinicaltrials.gov identifier:
NCT06964009 (https://clinicaltrials.gov/show/NCT06964009)

Treatment
Treatment study for people with recurrent platinum-resistant ovarian cancer

Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study

https://www.facingourrisk.org/research-clinical-trials/study/394 /multi-cancer-detection-blood-tests-in-adults-without-cancer-vanguard-study

Clinicaltrials.gov identifier:
NCT06995898 (https://clinicaltrials.gov/show/NCT06995898)

Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer

A Study of the Drug Romosozumab in People With Metastatic Breast Cancer and Osteoporosis

https://www.facingourrisk.org/research-clinical-trials/study/433 /a-study-of-the-drug-romosozumab-in-people-with-metastatic-breast-cancer-and-osteoporosis

Clinicaltrials.gov identifier:
NCT07776613 (https://clinicaltrials.gov/show/NCT07776613)

Quality of Life
Study for people with metastatic breast cancer and osteoporosis

Family Study for People with Certain Rare BRCA1 or BRCA2 Variants

https://www.facingourrisk.org/research-clinical-trials/study/428 /family-study-for-people-with-certain-rare-brca1-or-brca2-variants

Surveys, Registries, Interviews
Family study for adults with a known rare BRCA1 or BRCA2 variant in themselves or a relative

Psilocybin Therapy in Advanced Cancer

https://www.facingourrisk.org/research-clinical-trials/study/436 /psilocybin-therapy-in-advanced-cancer

Clinicaltrials.gov identifier:
NCT05398484 (https://clinicaltrials.gov/show/NCT05398484)

Quality of Life
Study for people with advanced cancer

Comparing Treatment with Sacituzumab Govitecan and Bevacizumab to Chemotherapy and Bevacizumab for Recurrent Ovarian Cancer After PARP Inhibitor Maintenance Therapy

https://www.facingourrisk.org/research-clinical-trials/study/439 /comparing-investigational-drug-combination-sacituzumab-govitecan-with-bevacizumab-to-chemotherapy-for-treating-recurrent-ovarian-cancer-after-parp-inhibitor-maintenance-therapy

Clinicaltrials.gov identifier:
NCT07504588 (https://clinicaltrials.gov/show/NCT07504588)

Treatment
Study for platinum-sensitive ovarian cancer that has progressed after PARP inhibitor

Please Help us Learn More About Immunotherapy Side Effects That People With Cancer Experience

https://www.facingourrisk.org/research-clinical-trials/study/421 /a-5-minute-patient-and-caregiver-survey-to-share-experiences-with-immunotherapy-and-any-short-term-or-long-term-side-effects

Surveys, Registries, Interviews
This 5-minute survey allows cancer patients on immunotherapy (currently or in the past) and their caregivers to share their experiences, including their side effects and whether they were resolved or not.

Study of Dostarlimab Immunotherapy in People with Mismatch Repair-Deficient Endometrial Cancer Who Wish to Preserve Fertility

https://www.facingourrisk.org/research-clinical-trials/study/434 /a-phase-ii-study-of-dostarlimab-immunotherapy-in-people-with-mismatch-repair-deficient-endometrial-who-wish-to-preserve-fertility

Clinicaltrials.gov identifier:
NCT04165772 (https://clinicaltrials.gov/show/NCT04165772)

Treatment
Treatment study for people with MSI-H or dMMR early-stage endometrial cancer.

The FYI on MRI: A Decision Support Intervention for Screening Breast MRI for Black and Latina Women

https://www.facingourrisk.org/research-clinical-trials/study/406 /the-fyi-on-mri-a-decision-support-intervention-for-screening-breast-mri

Clinicaltrials.gov identifier:
NCT06892275 (https://clinicaltrials.gov/show/NCT06892275)

Surveys, Registries, Interviews
Feedback survey on materials about breast MRI

A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment

https://www.facingourrisk.org/research-clinical-trials/study/414 /a-study-to-learn-about-the-study-medicine-called-pf-07248144-in-combination-with-fulvestrant-in-people-with-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer-who-progressed-after-a-prior-line-of-treatment

Clinicaltrials.gov identifier:
NCT07062965 (https://clinicaltrials.gov/show/NCT07062965)

Treatment
Study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment

Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)

https://www.facingourrisk.org/research-clinical-trials/study/397 /comparing-shorter-vs-standard-radiation-for-high-risk-prostate-cancer

Clinicaltrials.gov identifier:
NCT05946213 (https://clinicaltrials.gov/show/NCT05946213)

Treatment
Treatment study for high-risk prostate cancer

PREVAIL Study: A Genetic Education and Genetic Testing Study for African American Men with Prostate Cancer or with a Strong Family History of Cancer

https://www.facingourrisk.org/research-clinical-trials/study/448 /prevail-study-a-genetic-education-and-genetic-testing-study-for-african-american-men-with-prostate-cancer-or-with-a-strong-family-history-of-cancer

Prevention
Genetic testing for African American men with prostate cancer or cancer in the family

Testing the Drug CX-5461 for Treating Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/431 /testing-the-drug-cx-5461-for-treating-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT06606990 (https://clinicaltrials.gov/show/NCT06606990)

Treatment
Phase 1 study for treatment of advanced solid tumors

Virtual ACT and Compassion-Based Group Therapy for Cancer-Related Well-Being

https://www.facingourrisk.org/research-clinical-trials/study/442 /virtual-act-and-compassion-based-group-therapy-for-cancer-related-well-being

Clinicaltrials.gov identifier:
NCT06246955 (https://clinicaltrials.gov/show/NCT06246955)

Quality of Life
Adults with solid tumors or blood cancers who are receiving care at Mayo Clinic in AZ and experiencing stress or challenges related to cancer

Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)

https://www.facingourrisk.org/research-clinical-trials/study/389 /using-the-drug-daraxonrasib-in-surgically-removed-pancreatic-cancer-rasolute-304

Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)

Treatment
Study for pancreatic cancer treatment after surgery and chemotherapy

Comparing the Targeted Therapy Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (RASolute 303)

https://www.facingourrisk.org/research-clinical-trials/study/407 /comparing-daraxonrasib-with-or-without-chemotherapy-to-chemotherapy-alone-for-first-line-treatment-of-metastatic-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT07491445 (https://clinicaltrials.gov/show/NCT07491445)

Treatment
Study for First-Line Treatment of Metastatic Pancreatic Cancer

Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)

https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8

Clinicaltrials.gov identifier:
NCT06395519 (https://clinicaltrials.gov/show/NCT06395519)

Treatment
Treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer

Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/392 /evaluating-the-safety-of-nipple-sparing-mastectomy-in-women-with-a-high-risk-for-breast-cancer

Clinicaltrials.gov identifier:
NCT06888388 (https://clinicaltrials.gov/show/NCT06888388)

Prevention
Study for people considering double mastectomy to reduce breast cancer risk

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.